NASDAQ:OTIC - Otonomy Stock Price, Forecast & News

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Otonomy Inc (NASDAQ:OTIC) released its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.12. The biopharmaceutical company had revenue of $0.13 million for the quarter, compared to analysts' expectations of $0.31 million. Otonomy had a negative net margin of 6,516.78% and a negative return on equity of 72.06%. View Otonomy's Earnings History.

Otonomy is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Otonomy.

4 analysts have issued twelve-month price targets for Otonomy's shares. Their forecasts range from $5.00 to $8.00. On average, they expect Otonomy's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 91.8% from the stock's current price. View Analyst Price Targets for Otonomy.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Otonomy.

Media headlines about OTIC stock have trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Otonomy earned a news sentiment score of 0.5 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the near term. View News Stories for Otonomy.

Otonomy saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 131,200 shares, an increase of 5.2% from the November 28th total of 124,700 shares. Based on an average daily trading volume, of 99,000 shares, the short-interest ratio is presently 1.3 days. Currently, 0.5% of the company's shares are sold short. View Otonomy's Current Options Chain.

Some companies that are related to Otonomy include ProQR Therapeutics (PRQR), BioSpecifics Technologies (BSTC), Aptorum Group (APM), Atreca (BCEL), Verrica Pharmaceuticals (VRCA), Progenics Pharmaceuticals (PGNX), Avedro (AVDR), Calithera Biosciences (CALA), AMAG Pharmaceuticals (AMAG), Merus (MRUS), Kindred Biosciences (KIN), Lannett (LCI), 89bio (ETNB), Puma Biotechnology (PBYI) and Recro Pharma (REPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Corbus Pharmaceuticals (CRBP), Catabasis Pharmaceuticals (CATB), Melinta Therapeutics (MLNT), Intercept Pharmaceuticals (ICPT), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), ACADIA Pharmaceuticals (ACAD), Strongbridge Biopharma (SBBP), Spectrum Pharmaceuticals (SPPI) and Marathon Oil (MRO).

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OTIC stock can currently be purchased for approximately $3.65.

Otonomy has a market capitalization of $112.24 million and generates $750,000.00 in revenue each year. The biopharmaceutical company earns $-50,370,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Otonomy employs 49 workers across the globe.View Additional Information About Otonomy.

The official website for Otonomy is http://www.otonomy.com/.

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]